Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATP7B
REST API REST API
Homo sapiens
ATP7B is differentially expressed in 241 experiments: 94 organism parts: liver, cerebellum, ... (92 more);, 140 disease states: normal, glioblastoma, ... (138 more);, 58 cell types 324 cell lines 30 compound treatments and 75 other conditions.
Synonyms WND
Orthologs Atp7b (Rattus norvegicus)   F1MKI1_BOVIN (Bos taurus)   ATP7B (Danio rerio)   F1N8W2_CHICK (Gallus gallus)   Atp7b (Mus musculus)   ATP7 (Drosophila melanogaster)   CCC2 (Saccharomyces cerevisiae)   F6SW46_CIOIN (Ciona intestinalis)   atp7b (Xenopus laevis)   NP_001020438.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term ATPase activity, coupled to transmembrane movement of ions, phosphorylative mechanism, response to copper ion, protein binding, cytoplasm, copper-exporting ATPase activity, intracellular, metal ion transport, membrane, cellular copper ion homeostasis, Golgi membrane, Golgi apparatus, metabolic process, metal ion binding, cation transport, late endosome, membrane fraction, basolateral plasma membrane, ATP binding, sequestering of calcium ion, integral to plasma membrane, copper ion import, copper ion transport, cytoplasmic membrane-bounded vesicle, nucleotide binding, ATP biosynthetic process, perinuclear region of cytoplasm, integral to membrane, hydrolase activity, trans-Golgi network, transmembrane transport, catalytic activity, copper ion binding, mitochondrion, cellular zinc ion homeostasis, copper-transporting ATPase activity, lactation, ATP catabolic process, copper ion export, intracellular copper ion transport, ion transmembrane transport
InterPro Term Dehalogen-like_hydro, ATPase_P-typ_heavy-metal, ATPase_P-typ_H-transp, HAD-SF_hydro-like_3, ATPase_P-typ_ion-transptr, ATPase_P-typ_cat/Cu-transptr, ATPase_P-typ_ATPase-assoc-dom, HG_scavenger, HMA_Cu_ion-bd, HeavyMe-assoc_HMA
Gene-Disease Assocation WILSON DISEASE
UniProt Accession D3KCZ0, A6N865, C0LF55, A7UAV8, P35670, A7UDR4, A6YQZ0, A6YQZ1, C8BMD5, E7EQQ2, E7ET55, F6XIH0, F5H748, F5H562
Search EB-eye ENSG00000123191
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
SW480
4
E-MEXP-1014, E-GEOD-18005, E-MTAB-37, E-GEOD-2509
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
SW620
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-2509
HL-60
1
2
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
318 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21750, ... (34 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-18147
fibroblast
2
E-GEOD-3920, E-GEOD-26672
stromal cell
1
2
E-MEXP-2034, E-GEOD-1460, E-MEXP-1327
nucleus pulposus
1
E-MEXP-2488
platelet
1
E-GEOD-2006
macrophage
1
E-GEOD-22373
52 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-2466, E-GEOD-4045, ... (42 experiments)

Factor Value U/D Experiments
chronic myelogenous leukemia
4
E-GEOD-96, E-MTAB-62, E-MTAB-37, E-GEOD-5550
Burkitt's lymphoma
3
E-MTAB-37, E-GEOD-96, E-GEOD-1880
lung carcinoma
2
E-MTAB-37, E-GEOD-6014
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
choriocarcinoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-37, E-MTAB-62
134 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (20 experiments)

Factor Value U/D Experiments
none
1
8
E-GEOD-5824, E-MEXP-1230, E-GEOD-412, E-GEOD-2803, E-TABM-868, ... (9 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
sevoflurane
1
E-GEOD-4386
ethanol
1
E-GEOD-3113
baseline sevoflurane
1
E-GEOD-4386
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
24 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2034, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-3325, E-GEOD-2509, E-TABM-147, E-GEOD-21138, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-4006

Genotype
studied in E-GEOD-3494, E-GEOD-12662, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-GEOD-19519, E-GEOD-6919, ... (23 experiments)

Infection
studied in E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743, E-GEOD-5372

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1493, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-11428

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19815

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.399 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM